Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mediwound Ltd Ord Sh
(NQ:
MDWD
)
16.98
-0.31 (-1.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mediwound Ltd Ord Sh
< Previous
1
2
Next >
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
April 26, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update
March 16, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
March 16, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth
March 06, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
March 02, 2023
Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
February 23, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
February 07, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
February 03, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
December 29, 2022
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
December 23, 2022
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Strengthens European Presence of NexoBrid®
December 20, 2022
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
December 19, 2022
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Expands Global Presence as NexoBrid® Gains Approval in India
December 13, 2022
Exclusive marketing and distribution agreement signed with Bharat Serum and Vaccines Limited (BSV), a leading biopharmaceutical company
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces a 1-for-7 Reverse Share Split
December 05, 2022
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Report Third Quarter 2022 Financial Results
November 03, 2022
Conference Call and Webcast Scheduled for Tuesday, November 15, 2022 at 8:30 am Eastern Time
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Formation of Strategic Advisory Board
October 25, 2022
Esteemed group of industry leaders to contribute expertise and experience to MediWound’s strategic and operational activities
From
MediWound Ltd.
Via
GlobeNewswire
MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022
October 18, 2022
EscharEx’s promising results from the completed Phase 2 trials were highlighted
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings
October 07, 2022
Gross Proceeds of $30.5 Million Raised
From
MediWound Ltd.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.